Kelley Wright
Investment Q Trends
Chuck Carlson
The DRIP Investor
Paul Goodwin
Cabot China & Emerging Markets Report
John Reese
Validea

Health care stocks: A Supreme decision


Bookmark and Share
By Todd Rosenbluth, S&P Capital IQ ETF Analyst, The Outlook

S&P The OutlookA decision regarding the constitutionality of the health care reform law is expected by the Supreme Court in mid-June 2012.

Below, we discuss some potential actions by the Court and the impact we think they could have on various health care industries. We also look at the impact on Health Care Select Sector SPDR Fund (XLV), the largest health care ETF by far with $4.4 billion in assets.

There are three potential scenarios arising from the Court decision, says Jeffrey Loo, head of health care equity research for S&P Capital IQ.

The best scenario for the health care industry, he says, would be a ruling that the individual mandate is constitutional, allowing the health care reform law to be implemented as scheduled.

Under this scenario, the health care sector would benefit from approximately 32 million additional insured customers (phased in from 2014 to 2019), positively impacting health care facilities, managed health care companies, health care service providers, and health care distributors.

Another scenario is the Court rules the individual mandate unconstitutional and cannot be severed from the rest the Court would invalidate the individual mandate along with the rest of the health care reform law package.

S&P Capital IQ believes this scenario would have a neutral impact on the overall health care industry. In spite of losing its largest potential growth driver (the 32 million additional insured Americans), burdensome concessions, regulations, fees, and taxes would likely be dropped as well.

The last scenario is the Court ruling the individual mandate is unconstitutional, but leaving the rest of the health care reform law package intact. S&P Capital IQ believes this would be the worst-case scenario for health care companies.

Under this scenario, the concessions, regulations, fees, and taxes various sub-industries agreed to in exchange for the potential of 32 million additional insured Americans would remain, unless new legislation scales them back.

The Congressional Budget Office estimates that if the individual mandate is struck down, only 16 million additional Americans would obtain insurance, with the vast majority coming from the expansion of Medicaid (assuming the Court determines the expansion of Medicaid is lawful anyway).

Medicaid customers generate the lowest margins for the health care sector. Loo believes the companies most adversely impacted would include health care facilities, pharmaceuticals, managed health care, and health care services.

As of April 2012, 51% of the assets in XLV were in pharmaceuticals, including five of its 10 largest holdings: Abbott Laboratories (ABT), Bristol-Myers Squibb (BMY), Johnson & Johnson (JNJ), Merck (MRK) and Pfizer (PFE). These stocks all earn our buy rating.

Herman Saftlas, the equity analyst who covers these stocks for S&P Capital IQ, believes that pharmaceuticals would be among the groups most affected by any decision, with the likely impact less pronounced for the managed care and hospital areas.

Overall, Saftlas favors the aforementioned stocks for their growth potential and generous dividend yields.

The next two largest sub-industries in XLV are health care equipment (16%) and biotechnology (11%). S&P Capital IQ equity analysts are more positive on the fundamentals of biotechnology than equipment and have a buy recommendation on Amgen (AMGN).

Rounding out the five largest sub-industries for XLV are managed health care (9%) and health care services (5%), with respective holdings such as S&P Capital IQ buy recommended UnitedHealth Group (UNH) and strong buy recommended Express Script Holdings (ESRX).

Overall, despite the overhang of the Supreme Court review of healthcare reform, we think the Health Care Select SPDR Fund is worthy of investor attention.

Learn more about this financial newsletter at Standard & Poor's The Outlook.

Related articles:


Advertisement
Banner
News Flash

US Natural Gas ETF: On a roll
by Doug Fabian, editor Successful Investing

One area I think is ready for a new buy is natural gas. After experiencing a sharp decline from November through early January, natural gas prices have been on a roll.


Read more...

 

Split buys? HOMB and Noble Energy
by Neil Macneale, editor 2-for-1 Stock Split Newsletter

Each month, we add one stock to our model portfolio based upon those companies that have announced 2-for-1 stock splits; after a meager number of splits over the past year, we have a nice collection of six splits elect from this month.


Read more...


   

WisdomTree targets global bonds
by Mark Salzinger, editor The Investor's ETF Report

While most investors diversify the equity portions of their portfolio with allocations to foreign stocks, few diversify their bond holdings internationally. WisdomTree recently introduced the first ETF to invest in a truly global portfolio of corporate bonds.


Read more...

 

Express Scripts: Obamacare buy
by J. Royden Ward, editor Cabot Benjamin Graham Value Investor

I am attracted to healthcare stocks because the confusion surrounding “ObamaCare” has held healthcare stock prices back. I think Express Scripts (ESRX) is very likely to shine in 2013.


Read more...

 

Hodges: High conviction funds
by Walter Frank, editor MoneyLetter

Over the last two months, Hodges Fund (HDPMX) has made a strong run to the top echelons of our domestic stock fund rankings. And one of its siblings, Hodges Small Cap (HDPSX) has been within the top decline of the small blend category from 2009 through last year, and is in the top 20% this year.


Read more...

 

United Natural: A play on Whole Foods
by Mark Skousen, editor Hedge Fund Trader Alert

We’ve recommended Whole Foods Market (WFM) from time to time, and the stock has moved up sharply in the past three years, but I’d like to suggest an alternative -- one of Whole Foods’ primary suppliers, United Natural Foods (UNFI).


Read more...

 

Timing expert eyes India
by Sy Harding, editor Street Smart Report

The money flow and momentum reversals in India's Bombay Index have now been enough to trigger buy signals on intermediate-term indicators. With this new buy signal, we have added a position in the iShares India 50 ETF (INDY) to our portfolio.


Read more...

 

Value investor goes with Guess
by Charles Mizrahi, editor Hidden Values Alert

Guess?, Inc. (GES) is a holding in our special situation portfolio; its strong product quality has created brand name recognition and a loyal consumer following.


Read more...

 

MGAM: Bingo, lotteries, casinos
by Jim Oberweis, Jr., editor The Oberweis Report

Multimedia Games Holding Company (MGAM) makes innovative gaming systems for Native American and commercial casino operators in North America, lottery operators, and charity and commercial bingo operators.


Read more...

 

Fidelity expert: Bowers' bond bets
by Jack Bowers, editor Fidelity Monitor & Insight

If you’ve been worried that the bond market might take a big hit, you can relax. Indeed, while bond funds may lag stock funds over the next 5-10 years, they still have a decent shot at keeping up with inflation, and they remain an excellent way to cut risk in a blended portfolio.


Read more...

 



Banner



Close
Select Offer: Schwab Options Market Commentary